- Home
- MAS vs FEMY Comparison
MAS vs FEMY Comparison
Compare MAS & FEMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MAS
- FEMY
- Stock Information
- Founded
- MAS 1929
- FEMY 2004
- Country
- MAS United States
- FEMY United States
- Employees
- MAS N/A
- FEMY N/A
- Industry
- MAS Industrial Specialties
- FEMY Medical/Dental Instruments
- Sector
- MAS Industrials
- FEMY Health Care
- Exchange
- MAS Nasdaq
- FEMY Nasdaq
- Market Cap
- MAS 15.9B
- FEMY 12.5M
- IPO Year
- MAS N/A
- FEMY 2021
- Fundamental
- Price
- MAS $73.64
- FEMY $0.39
- Analyst Decision
- MAS Buy
- FEMY Strong Buy
- Analyst Count
- MAS 14
- FEMY 3
- Target Price
- MAS $74.86
- FEMY $7.33
- AVG Volume (30 Days)
- MAS 2.0M
- FEMY 2.8M
- Earning Date
- MAS 10-28-2025
- FEMY 11-11-2025
- Dividend Yield
- MAS 1.68%
- FEMY N/A
- EPS Growth
- MAS N/A
- FEMY N/A
- EPS
- MAS 3.76
- FEMY N/A
- Revenue
- MAS $7,663,000,000.00
- FEMY $1,887,016.00
- Revenue This Year
- MAS N/A
- FEMY $103.55
- Revenue Next Year
- MAS $3.39
- FEMY $148.13
- P/E Ratio
- MAS $19.59
- FEMY N/A
- Revenue Growth
- MAS N/A
- FEMY 98.61
- 52 Week Low
- MAS $56.55
- FEMY $0.31
- 52 Week High
- MAS $86.70
- FEMY $1.80
- Technical
- Relative Strength Index (RSI)
- MAS 53.07
- FEMY 31.02
- Support Level
- MAS $73.00
- FEMY $0.35
- Resistance Level
- MAS $75.42
- FEMY $0.57
- Average True Range (ATR)
- MAS 1.38
- FEMY 0.05
- MACD
- MAS -0.25
- FEMY 0.01
- Stochastic Oscillator
- MAS 44.32
- FEMY 29.11
About MAS Masco Corporation
Masco manufactures a variety of home improvement and building products. The company's $5-billion plumbing segment, led by the Delta and Hansgrohe brands, sells faucets, showerheads, and other related plumbing fixtures and components. The roughly $3-billion decorative architectural segment primarily sells paints and other coatings under the Behr and Kilz brands, but it also sells builder hardware products.
About FEMY Femasys Inc.
Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets.